Show results for
Refine by
Therapeutic Candidate Suppliers Serving Belarus
28 companies found
based inNewcastle Upon Tyne, UNITED KINGDOM
Newcells offers expert disease modelling services using best in class in vitro platforms and supports drug development by providing robust data for regulatory submissions and the critical decision-making process. Newcells mission is to de-risk the ...
In vitro assessment of Fibroblast-to-Myofibroblast transition (FMT). Newcells offers a fast and reliable FMT assay service to evaluate the efficacy of anti-fibrotic compounds using high-content imaging. This customisable, high-throughput assay is ...
based ins-Hertogenbosch, NETHERLANDS
We make up a top-class and diverse team of experts, with the right combination of knowledge and expertise to jointly tackle the data analysis and software engineering challenges related to the field of immunomics. Together with our scientific and ...
Antibody display campaigns can generate numerous datasets. The analysis of this data is slow, resource-intensive, and picking candidates often relies on making decisions on a ...
based inCarlsbad, CALIFORNIA (USA)
Our mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions. Lineage’s programs are based on the Company’s proprietary cell-based therapy platform and associated ...
based inSchlieren, SWITZERLAND
Redbiotec is a private biotech company in Zurich-Schlieren. Founded in 2006 as a spin-off of ETH Zürich, the company has won several awards, including the renowned W.A. de Vigier Award. In 2015, Pfizer acquired Redvax (a Redbiotec spin-off) for its ...
Redbiotec specializes in developing high-quality vaccines to fight difficult diseases. After successfully spinning out the CMV vaccine program that was acquired by Pfizer, Redbiotec is currently developing HSV-2 therapeutic vaccine ...
based inHercules, CALIFORNIA (USA)
Bio-Rad is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for 70 years, our products ...
Reduce Lead Time for Antibody Generation: Assays supporting SARS-CoV-2 vaccine, therapeutic, and diagnostic test development must be robust, scalable, and transferable to laboratories worldwide. They need to be designed and validated rapidly, yet ...
based inOss, NETHERLANDS
Founded in 2010, Synaffix is a biotech company with a clinical-stage platform technology that enables best-in-class antibody-drug conjugates (ADCs), bispecific antibodies and other targeted therapeutics under a technology out-licensing business ...
based inDijon, FRANCE
Oncodesign is a biopharmaceutical company that offers you powerful technologies and tools to guide you through the development of your drug, from medicinal chemistry to drug candidate. Our therapeutic areas are expanding. In addition to oncology, ...
based inSomerset, NEW JERSEY (USA)
As the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world, we conduct all our business responsibly and with integrity. Our ...
To date, over 600 different mAb and mAb fusions and over 160+ different recombinant proteins have been produced using the GPEx system, with 160+ clinical trials utilizing therapeutic candidates developed using GPEx ...
based inAnn Arbor, MICHIGAN (USA)
BlueWillow Biologics is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines using its patented nanoemulsion platform. The platform, originally discovered at the University of ...
Herpes simplex virus-2 (HSV-2) is the leading cause of genital herpes, a sexually transmitted disease affecting over 500 million people worldwide. BlueWillow’s intranasal nanoemulsion (NE) vaccine is uniquely suited to offer protection against ...
based inBrisbane City, AUSTRALIA
Microba’s precise microbiome analysis is built on the expertise of our innovative team at the leading edge of microbiome science. Our approach to microbiome analysis is enabling new discoveries and advancing the understanding of the microbiome in ...
Developing novel therapeutics from the human microbiome; The uncultured portion of the human gut microbiome, which is the majority of microbial species, represents untapped therapeutic opportunity. Microba has established a platform for drug ...
based inTübingen, GERMANY
Founded in 2015, Atriva Therapeutics is a biopharmaceutical company specifically pioneering the development of host-targeting antiviral therapies set up by a team of leading scientists in viral research and seasoned industry experts. The company ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
Advances in the field of immuno-oncology have led to new and better treatment outcomes for a range of cancers, and particularly, blood cancers. However, even with the advent of checkpoint inhibitors as immunotherapies for solid tumors, significant ...
based inPhiladelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell therapies have advantages over other immune ...
based inJupiter, FLORIDA (USA)
Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and ...
We are building an active pipeline of products for human health by applying our proprietary and patented C1 technology to develop vaccines and antibodies for infectious and other diseases. Vaccine Development: The C1 platform is ready for full ...
based inVerona, ITALY
At Sibylla Biotech, we face the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs. Born out of a scientific challenge, the PPI-FIT protocol (Pharmacological Protein Inactivation by Folding ...
based inLund, SWEDEN
Carbiotix is an award-winning biotechnology company pioneering microbiome healthcare through a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics, along side a range of cost-effective gut health testing ...
Carbiotix believes that activity within the gut microbiome is more important than the presence of specific bacteria species. As such, the company focuses on engineering microbiome modulators (proprietary second-generation soluble fibres, isolated ...
based inWroclaw, POLAND
Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based ...
Therapies targeting immunological checkpoints, or more specifically their inhibition, promise effective treatment options for patients with metastatic forms of this disease. In the PB001 project, Pure Biologics aims to develop a recombinant ...
based inSan Diego, CALIFORNIA (USA)
Vala Sciences helps researchers achieve an unrivaled in vitro understanding of how human cells respond to drug compounds. Vala is committed to providing expert services to pharmaceutical developers and researchers to help overcome the persistent ...
based inLeiden, NETHERLANDS
A leading pioneer in leveraging iPSC innovation for drug discovery. The catalyst with the requisite iPSC know-how and experience to empower innovators in drug discovery to advance their science relentlessly, consistently and efficiently. For the ...
Human-induced pluripotent stem cell (iPSC) derived atrial cardiomyocytes are a powerful tool to improve in vitro testing of new treatments for atrial arrhythmias. Our team can manufacture atrial cardiomyocytes at the scale needed from the iPSC that ...
based inCupertino, CALIFORNIA (USA)
ALZET Osmotic Pumps were developed during the 1970’s by ALZA Corporation. They were initially developed for use during internal company research, and for use by some of ALZA’s collaborators working at academic institutions. It did not take long for ...